Organization
St Vincent's Hospital
7 clinical trials
10 abstracts
Abstract
Mutated KRAS as a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment.Org: Northern Health, Peter MacCallum Cancer Centre, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne Health,
Clinical trial
A Window of Opportunity Study of Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Hormone Receptor-positive Breast Cancer.Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate CancerStatus: Completed, Estimated PCD: 2023-08-30
Clinical trial
Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate CancerStatus: Completed, Estimated PCD: 2023-06-06
Clinical trial
High Dose Testosterone + Carboplatin in Men With Advanced Prostate CancerStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC ObstructionStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Assessment of the Diagnostic and Theranostic Potential of Ga Bombesin PET/CT (NeoB) Imaging for Staging of ER/PR + HER2- Breast Cancer Patients With Metastatic Disease: Comparison to Conventional ImagingStatus: Recruiting, Estimated PCD: 2025-02-20
Abstract
Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples.Org: ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, The University of Sydney, Westmead and Blacktown Hospitals,
Abstract
A proteomic signature associated with prognosis in HPV-related locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Department of Otolaryngology, Head and Neck Surgery, Princess Alexandra Hospital, ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Princess Alexandra Hospital and Faculty of Medicine at University of Queensland,
Abstract
Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.Org: NHMRC Clinical Trials Centre, The University of Sydney, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
Successful management of Australian patients with locally advanced keratinocyte cancer (KC) and/or extensive skin field cancerization (ESFC), using widefield volumetric arc radiation therapy (VMAT): Report with 24-month follow-up.Org: GenesisCare, Fort Myers, FL, St. Vincent's Hospital, Veracity Clinical Research, University of Sydney and Sydney Cancer Centre, St Vincent's Hospital,
Abstract
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Org: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia, Sydney, Australia, Garvan Institute of Medical Research,
Abstract
Implementation study of a novel brief clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 Implementation Study).Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia, Chris O'Brien Lifehouse, Camperdown, NSW, Australia,
Abstract
Circulating ether lipids in prostate cancer.Org: Chris O'Brien Lifehouse, Garvan Institute of Medical Research, Baker Institute, Baker Heart and Diabetes Institute, St Vincent's Hospital,
Abstract
Cancer survivorship: Patient experiences on early phase trials during the COVID-19 pandemic—Qualitative study from an Australian Phase 1 unit.Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia, NSW Health Pathology, Australian Catholic University,